Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 9/20 | 0.74 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.74 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.74 |
| ▸ | GSK3B | P49841 | 1/20 | 0.74 |
| ▸ | MERTK | Q12866 | 1/20 | 0.74 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.72 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.72 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | CDK4 | P11802 | 2/20 | 0.72 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.72 |
| ▸ | CDK2 | P24941 | 2/20 | 0.72 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | PAK4 | O96013 | 1/20 | 0.72 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29444630 | 0.87 | CDK5 (0.74) | CDK1CCNB1EIF2AK2GSK3BMERTK | |
| SCHEMBL5840458 | 0.87 | CDK5 (0.74) | CDK1CCNB1EIF2AK2GSK3BMERTK | |
| SCHEMBL31694379 | 0.86 | CDK1 (1.00) | CDK1CCNB1EIF2AK2GSK3BMERTK | |
| SCHEMBL7093069 | 0.86 | CDK1 (0.79) | CDK1CCNB1EIF2AK2GSK3BMERTK | |
| SCHEMBL1181087 | 0.86 | CDK1 (1.00) | CDK1CCNB1EIF2AK2GSK3BMERTK | |
| SCHEMBL5840520 | 0.86 | CDK1 (0.82) | CDK1CCNB1EIF2AK2GSK3BMERTK | |
| SCHEMBL31484383 | 0.86 | CDK1 (1.00) | CDK1CCNB1EIF2AK2GSK3BMERTK | |
| SCHEMBL5749121 | 0.85 | CDK1 (0.70) | CDK1CCNB1EIF2AK2GSK3BMERTK | |
| SCHEMBL13168058 | 0.85 | CDK1 (0.72) | CDK1CCNB1EIF2AK2GSK3BMERTK | |
| SCHEMBL27769157 | 0.85 | CDK5 (0.72) | CDK1CCNB1EIF2AK2GSK3BMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10722515-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | SRI INTERNATIONAL (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190255059-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | SRI INTERNATIONAL | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10722515-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | CLK2, CLK1, CLK3 | CDK1 6/4885CCNB1 251/4885EIF2AK2 143/4885 |
| US-20190255059-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | CLK2, CLK1, CLK3 | CDK1 8/4885CCNB1 259/4885EIF2AK2 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.